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SUMMARY
Hippo-Lats-Yorkie signaling regulates tissue overgrowth and tumorigenesis in Drosophila. We show that the
Mst1 and Mst2 protein kinases, the mammalian Hippo orthologs, are cleaved and constitutively activated in
themouse liver. CombinedMst1/2 deficiency in the liver results in loss of inhibitory Ser127 phosphorylation of
the Yorkie ortholog, Yap1, massive overgrowth, and hepatocellular carcinoma (HCC). Reexpression of Mst1
in HCC-derived cell lines promotes Yap1 Ser127 phosphorylation and inactivation and abrogates their tumor-
igenicity. Notably, Mst1/2 inactivates Yap1 in liver through an intermediary kinase distinct from Lats1/2.
Approximately 30% of human HCCs show low Yap1(Ser127) phosphorylation and a majority exhibit loss of
cleaved, activatedMst1. Mst1/2 inhibition of Yap1 is an important pathway for tumor suppression in liver rele-
vant to human HCC.INTRODUCTION
Mst1 and Mst2 are 56–60 kDa class 2 GC kinases that share 76%
identity in amino acid sequence (Dan et al., 2001). Mst1/2 are the
closest mammalian homologs of the Drosophila Hippo kinase.
Loss of Hippo function (in the fly eye) results in massive over-
growth, due to an acceleration of cell cycle progression and
a failure of developmental apoptosis (Harvey et al., 2003; UdanCet al., 2003; Wu et al., 2003); Mst2 can complement Hippo loss
of function (Wu et al., 2003). The pathway downstream of Hippo
has been extensively characterized (Reddy and Irvine, 2008;
Zhao et al., 2008a); Hippo, when bound to the adaptor protein
Salvador/Shar-pei, phosphorylates the Lats/Warts kinase. Hippo
also phosphorylates the noncatalytic polypeptide Mats (Mob
as tumor suppressor), enabling the latter to promote Lats/Warts
autophosphorylation and activation. Active Lats/Warts in turnSIGNIFICANCE
The pathways that regulate quiescence and tumor suppression in the liver have not been fully elucidated. We show that the
Mst1 and Mst2 kinases are tumor suppressors and regulators of liver size in adults and that negative regulation of the tran-
scriptional coactivator, Yap1, is central to Mst1/2 tumor-suppressor function. Loss of both Mst1 and Mst2 is sufficient to
initiate hepatocyte proliferation, resulting in dramatic liver overgrowth, resistance to proapoptotic stimuli, and the develop-
ment of HCC. Mst1 and Mst2 promote phosphorylation of Yap1 and thereby suppress its oncogenic activity. Mst1/2 regu-
lation of Yap1 is tissue specific and, in the liver, involves an Mst1/2-regulated Yap1 kinase distinct from Lats1/2. Signifi-
cantly, the Mst-Yap1 pathway is disrupted in a substantial fraction of human HCCs.ancer Cell 16, 425–438, November 3, 2009 ª2009 Elsevier Inc. 425
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Yorkie, by promoting its binding to 14-3-3 and nuclear exit (Dong
et al., 2007). Yorkie’s actions are pro-proliferative and antiapop-
totic, and elimination of Yorkie is epistatic to loss of function of all
of the upstream elements named above (Huang et al., 2005). The
regulation of Hippo kinase activity is less well defined, although
elimination of the atypical cadherin, Fat, or both of the FERM
domain proteins, Merlin and Expanded, results in Yorkie-depen-
dent phenotypes resembling Hippo loss of function (Reddy and
Irvine, 2008).
Essentially all of these components have mammalian ortho-
logs, and the ability of Mst1/2 to phosphorylate Lats1/2 and
Mob1, as well as Lats1 phosphorylation and inhibition of Yap1,
the mammalian ortholog of Yorkie, have been observed in vitro
and in cell culture (Chan et al., 2005; Dong et al., 2007; Hao
et al., 2008; Praskova et al., 2008; Zhao et al., 2007). In addition,
cell-cell contact of cultured mammalian cells induces phosphor-
ylation and inactivation of Yap1, whereas overexpression of
Yap1 or inactivation of either Lats2 or NF2/Merlin bypasses
contact inhibition of growth (McPherson et al., 2004; Morrison
et al., 2001; Zhao et al., 2007). Similarly, mouse keratinocytes
lacking WW45, the ortholog of Salvador/Shar-pei, fail to activate
Mst1, phosphorylate Yap1, and exit the cell cycle during differ-
entiation in vitro (Lee et al., 2008). Consistent with a function
as tumor suppressors, inactivating mutations in NF2 and
WW45 have been observed in a number of human cancers,
and Lats1 knockout mice develop soft tissue sarcomas and
ovarian cancers (McClatchey and Giovannini, 2005; McPherson
et al., 2004; Tapon et al., 2002). Yap1 is amplified in a number of
human tumor types and transgenic overexpression of Yap1 in
mice leads to liver overgrowth and hepatocellular carcinoma
(HCC) as well as expansion of progenitor cells in multiple organs
(Camargo et al., 2007; Dong et al., 2007; Overholtzer et al., 2006;
Zender et al., 2006). Whether Yap1 is regulated by the mamma-
lian Hippo pathway in vivo and whether loss of function of the
growth inhibitory components of the pathway results in defects
in organ size regulation has not been established.
Recent insight into the physiologic role of Mst1 has come from
the phenotype ofMst1-deficient mice, and here a rather different
picture emerges from that predicted from the Hippo paradigm
(Katagiri et al., 2009; Zhou et al., 2008). Mst1-deficient mice
exhibit greatly diminished numbers of mature, naive T cells in
peripheral lymphoid organs associated with defects in adhesion
and migration of the Mst1 null T cells. In addition, Mst1 null naive
T cells overproliferate upon stimulation of the T cell antigen
receptor. T cell adhesion requires the chemokine-induced clus-
tering and activation of integrins such as LFA-1; the latter, in turn,
requires the Rap1-GTP-dependent recruitment and activation of
Mst1 through its regulatory subunit, Nore1B (also called Rassf5B
or RAPL), a Ras/Rap1-GTP binding protein (Avruch et al., 2009;
Katagiri et al., 2006). The Mst1 substrate(s) mediating LFA-1
clustering/activation and the antiproliferative effects in naive
T cells are unknown. Although Mob1 phosphorylation is abol-
ished in the Mst1 null T cells, Mst1 deficiency causes little or
no change in the TCR-regulated phosphorylation of Lats1/2
and Yap1 (Zhou et al., 2008). Taken together, these findings indi-
cate that Mst1 and Mst2 participate in at least two signal trans-
duction pathways, perhaps in a tissue-specific manner, each
involving distinct upstream regulators and at least some different426 Cancer Cell 16, 425–438, November 3, 2009 ª2009 Elsevier Inctargets. Both pathways, however, generate antiproliferative out-
puts, suggesting that Mst1 and/or Mst2 may serve to suppress
tumor initiation. Here, we investigate the functions of Mst1/2 in
growth control, tumorigenesis, and Yap1 regulation in vivo using
genetically engineered mice.
RESULTS
Mst1 and Mst2 Are Required for Embryonic
Development and to Suppress HCC
We generated mouse strains with germline deletion of Mst1 and
Mst2 (Mst1 andMst2 alleles) (Zhou et al., 2008; see Figure S1,
available online); all studies were performed on a mixed (75%–
87.5% C57Bl/6) genetic background. Mst1/ mice were viable
and fertile but had a reduced number of mature naive T cells as
reported previously (Zhou et al., 2008); Mst2/ mice exhibit no
developmental or immunological defects and normal fertility.
Over a period of 18–24 months, 2/23 Mst1/ mice developed
lethal histiocytic sarcomas and 1/15 Mst2/ mice developed
a mammary tumor, whereas all wild-type mice (n = 15) remained
healthy.
To evaluate the genetic interaction between Mst1 and Mst2
deficiency, we intercrossed the Mst1 and Mst2 knockouts. The
Mst1+/Mst2+/, Mst1/Mst2+/, and Mst1+/Mst2/ animals
were viable, were fertile, and showed no developmental anoma-
lies (Figure S2). The Mst1/Mst2/ genotype, however,
resulted in embryonic lethality with first signs of retardation
evident at embryonic day 8.5 (E8.5) (Figure 1A). By E9.5 Mst1/
Mst2/ embryos were severely compromised (Figure 1A) and
not detected thereafter (Figure S2). Hence, a single functional
copy of Mst1 or Mst2 is both necessary and sufficient for normal
mouse development.
Necropsy at 3 and 5 months of age did not reveal obvious
defects in any of the viable genotypes. However, starting at
7 months of age, Mst1/Mst2+/ mice began to show signs of
illness, including lethargy and presence of a palpable abdominal
mass (the survival curve is shown in Figure 1B). Mst1/Mst2+/
animals showing morbidity (n = 13 of 16 animals by age 15
months) were euthanized and necropsies revealed that all mice
harbored liver tumors (ranging from 0.5 to 1.5 cm in greatest
diameter; Figure 1C). Some of these mice also displayed over-
growth (2- to 4-fold) of the apparently normal liver tissue. Lethal
liver tumors were also observed in 3/12 Mst1+/Mst2/ mice
by 15 months of age. Histological examination revealed that
the liver tumors in the Mst1/2 mutant mice were highly aggres-
sive hepatocellular carcinomas (HCCs) (Figure 1D). To further
document the incidence of HCC, we performed necropsies on
7-month-old asymptomatic animals. We observed HCCs in 6/7
Mst1/Mst2+/ mice, whereas none of the wild-type (n = 7) or
Mst1+/Mst2/ mice (n = 6) had visible tumors.
Dual Inactivation of Mst1 and Mst2 in HCC
PCR analysis of HCCs from Mst1/Mst2+/ mice revealed the
absence of wild-type Mst2, whereas adjacent normal liver
remained heterozygous for Mst2 (Figure 1E). Similarly, tumor-
specific loss of the wild-type Mst1 allele was seen in HCCs
from Mst1+/Mst2/ mice (Figure S3). Correspondingly, Mst1
and Mst2 proteins were undetectable in all HCCs analyzed, as
assessed by western blotting (Figure 1F, left, and data not.
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expression of Mst1 and Mst2. Unexpectedly, the majority of
Mst1 protein—and a substantial fraction of Mst2—in extracts
of normal liver is in the form of 34 kDa amino-terminal fragment
(Figure 1F, left). Previous studies have shown that the truncated
34 kDa form of Mst1 can arise from caspase-dependent
cleavage in response to apoptotic (Cheung et al., 2003; Graves
et al., 1998; Ura et al., 2001) or cell differentiation (Fernando
et al., 2002) signals and that this form has increased kinase
activity and altered substrate specificity (Anand et al., 2008).
Notably, we observe high levels of Mst1/2 activation in the
normal liver (as judged by phosphorylation at the Ser183/180
site; Praskova et al., 2004) and that the vast majority of the active
Mst1/2 kinase is in the form of the 34 kDa fragment (Figure 1F).
Although the 34 kDa polypeptide undergoes proteolytic degra-
dation during Mst1 immunoprecipitation (seen as a ladder of
polypeptides of faster mobility; Figure 1F, right), the majority of
the of the immunoprecipitated anti-pMst1(Ser183) immunoreac-
tivity is retrieved with the 34 kDa polypeptide, confirming its iden-
tity as the cleaved, activated form of Mst1. In the spleen, only full-
length Mst1 and Mst2 are observed (Figure 1G). These results
indicate that Mst1 and Mst2 are constitutively activated in the
quiescent adult liver and that homozygous inactivation of both
of these kinases in liver cells results in progression to HCC.
Hence Mst1 and Mst2 have partially redundant functions and
serve as critical HCC tumor suppressors. In addition, it appears
that tissue-specific cleavage may be an important mechanism of
Mst1/2 regulation in vivo.
Mst1 and Mst2 Are Critical Regulators of Quiescence
and Organ Size in the Adult Liver
To explore in more detail the role of Mst1 and Mst2 in liver
homeostasis, we sought to generate mice with homozygous
deficiency of both of these genes in the liver. To this end, we
introduced an Mst2 conditional knockout allele (Mst2F) onto an
Mst1 and Mst2 germline null background (generating Mst1/
Mst2F/F mice and Mst1/Mst2F/ mice). Adenovirus express-
ing Cre recombinase (Adeno-Cre) was injected into the tail vein
Figure 1. Phenotypes of Mst1/2 Mutant
Mice
(A) E8.5 Mst1/Mst2/ embryos (Aa) are smaller
than littermate controls with one or more func
tional Mst1 or Mst2 alleles (Ab). By E9.5, Mst1/
Mst2/ embryos (Ac and Ad) show various
degrees of developmental abnormalities (compare
with Ae) including stunted growth and failure to
turn and close the neural tube (Ad). Also, embryos
and yolk sacs (ys) appear pale and undervascular
ized and abnormally large pericardial cavities are
observed (Ac and Ad, indicated by arrowheads).
Scale bars represent 500 mm.
(B) Tumor free survival curve of mice of the indi
cated genotypes. All deaths in theMst1/Mst2+/
and Mst1
+/Mst2/ cohorts were due to HCC.
Statistical significance by the log rank test is indi
cated.
(C) Gross appearance of HCC arising in anMst1/
Mst2+/ mouse.
(D) H&E stained sections of murine HCC. The scale
bar on the left panel represents 500 mm; the scale
bar on the right panel represents 125 mm.
(E) PCR analysis of the wild type and null Mst1
(top) and Mst2 (bottom) alleles in normal liver
tissue from the indicated genotypes and of HCC
from Mst1/Mst2+/ mice (T1 and T2). Note that
the HCCs lack the wild typeMst1 andMst2 alleles.
(F) Shown on the left are western blots of liver from
a wild type mouse (N) and the normal liver from an
Mst1/Mst2+/ mouse (N) that bore an HCC (T).
Note the absence of total Mst1 and Mst2 and
phospho Mst1/2 in the HCC. In the wild type liver,
the majority of Mst1 and a significant proportion of
Mst2 is present as an amino terminal truncated
form (NT); Mst1/2 activity (as reflected by p Mst1/
2 levels) is restricted to the truncated Mst1/2 forms.
As shown on the right, Mst1 immunoprecipitate
from wild type and Mst1/ liver, demonstrating
immunoprecipitation of the truncated 34 kDa
polypeptide and the pMst1(Ser183) 34 kDa
polypeptide.
(G) Western blot showing that Mst1 is exclusively
full length in the spleen.Cancer Cell 16, 425–438, November 3, 2009 ª2009 Elsevier Inc. 427
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tion of Mst2; as controls, wild-type and Mst1/Mst2+/ mice
were also injected with Adeno-Cre. We confirmed the 90%
reduction of Mst2 in the livers of Adeno-Cre-injected Mst1/
Mst2F/F or Mst1/Mst2F/mice (designated Mst1/2 null livers)
compared to wild-type livers (Figure 2A). Remarkably, analysis at
serial time points revealed massive overgrowth of theMst1/2 null
livers. As early as 3 days after Adeno-Cre administration, a prom-
inent increase in liver size was noted (data not shown). TheMst1/
2 null livers were 2-fold larger than those from Adeno-Cre-
injected control animals at 8 days and 4-fold larger by 3 months
(Figures 2B and 2C). Ki-67 staining at day 8 showed that the
Mst1/2 null livers had an 4-fold increase in hepatocyte prolifer-
ation (Figures 2D and 2E). These data establish Mst1 and Mst2
as critical regulators of quiescence and organ size in the adult
liver.
The loss of the wild-type Mst1 and Mst2 alleles in the sponta-
neous HCC models described above suggested that complete
A
Actin
0   3 8 0 3 8
WT
Mst1 /
Mst2F/
Mst1(FL)
Mst1(NT)
Mst2(FL)
Mst2(NT)
pMst1/2(FL)
pMst1/2(NT)
HC
CAd Cre day:
WT     Mst1 / Mst2F/
B
Ad-Cre
Ad Cre day 8
Mst1 /
Mst2F/
D
WT
K
i-6
7+
/H
P
F
F
Ad Cre
 day 8
Weeks after Ad Cre
H
Cyclin D1
Cyclin D2
Cyclin D3
Cyclin E
PCNA
c Myc
p21
Actin
Ad Cre day: 0 3 8 0 3 8
WT Mst1 / Mst2F/
catenin*
HC
C
G
p21
catenin*
p53
Actin
Cyclin D3
Cyclin E
c Myc
S6K P
S6K
I
Mst2
Ms
t1-
/-M
st2
 F
/-
Ad Cre
8 d
1 2 3 4 5 6 7 8 9 10W
T
HCC
P<0 0001
P<0 0001
N S
P<0 0001
C
E
WT
Mst1-/-MstF/-
Figure 2. Acute Inactivation ofMst2 inMst1
Null Liver Initiates Hepatocyte Proliferation
and HCC Development
(A) Western blot showing expression of Mst1 and
Mst2 in the liver of mice of the indicated genotypes
before (day 0) or at intervals after Adeno Cre injec
tion in the tail vein. An HCC is shown (far right).
(B) Gross images of livers 8 days after Adeno Cre
administration.
(C) Liver weight to body weight ratios at various
time points after Adeno Cre delivery. Statistical
significance (unpaired t test) is indicated.
(D) Ki 67 staining at day 8; scale bars represent
500 mm.
(E) Quantitation of Ki 67 staining. Statistical signif
icance (unpaired t test) is indicated; error bars
show standard deviation.
(F) HCC free survival curve of mice of the indicated
genotypes treated at 6 weeks with Adeno Cre.
(G) Gross and H&E images of an HCC from an
Adeno Cre treated Mst1/Mst2F/ mouse. The
scale bar represents 500 mm.
(H) Western blot analysis of a series of cell cycle
regulators in liver tissue from WT and Mst1/
Mst2F/ mice before or at the indicated number
of days after Adeno Cre administration and in an
HCC.
(I) Western blot analysis of liver extracts from
wild type and Mst1/Mst2F/ mice 8 days after
Adeno Cre, and of a set of ten HCCs arising
after Adeno Cre treatment. b catenin* represents
b catenin dephosphorylated at Ser37 or Thr41.
loss of Mst1/2 signaling in liver cells might
be a rate-limiting step in HCC pathogen-
esis. Correspondingly, Mst1/Mst2F/F
and Mst1/Mst2F/ mice developed
lethal liver tumors with a mean latency of
10 weeks after Adeno-Cre injection (Fig-
ures 2F and 2G). Histological examination
revealed the presence of multifocal HCCs
against the backdrop of hyperplastic, but
untransformed, hepatocytes (Figure 2G).
To further validate theMst1/2 tumor-suppressor function in hepa-
tocytes, we crossed the Mst1/2 mutants with the Albumin-Cre
transgenic strain that specifically targets hepatocytes. Whereas
control mice showed no abnormalities, we found that 4/4
Albumin-Cre Mst1/Mst2F/F mice developed massively over-
grown livers and HCC by 3 months of age (Figure S4). The
tumor-specific loss of heterozygosity in the spontaneous HCC
models and the accelerated tumor development associated
with homozygous inactivation of both Mst1 and Mst2 in hepato-
cytes together suggest that Mst1/2 suppress HCC at least in
part through cell-autonomous mechanisms.
Regulation of Proliferative Signaling Pathways
by Mst1/2 in the Liver
To begin to address the downstream mechanisms associated
with loss of hepatocyte quiescence after Mst1/2 inactivation,
we profiled the expression of established cell-cycle regulators
in wild-type and Mst1/2 null livers. Cyclin D1 expression was428 Cancer Cell 16, 425–438, November 3, 2009 ª2009 Elsevier Inc.
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null liver—as assessed by both immunoblot analysis and qRT-
PCR—whereas there was an immediate upregulation of cyclin
D3 and cyclin E and a sharp decline in p21 levels (Figure 2H
and data not shown). These expression alterations were also
observed in a series of ten HCCs (Figure 2I). Hence,Mst1/2 inac-
tivation, and the ensuing entry of hepatocytes into the cell cycle,
is associated with an immediate and sustained alteration in regu-
lators of the G1 checkpoint. We also analyzed the expression of
a series of known regulators of hepatocyte proliferation and HCC
pathogenesis. c-Myc protein and mRNA were modestly induced
following acute Mst1/2 inactivation, whereas c-Myc levels were
greatly elevated in all HCCs analyzed (Figures 2H and 2I and
data not shown). The level of p70 S6 kinase phosphorylated at
Thr389/412, a site phosphorylated directly by mTOR complex
1, was markedly elevated by acute inactivation of Mst1/2 and
persisted at a high level in nearly all HCCs (Figure 2I). In contrast,
Akt(Ser473) phosphorylation, which has been proposed to be
negatively regulated by Mst1/2 (Cinar et al., 2007), was not
consistently altered by Mst1/2 inactivation or in the HCCs
(Figure S5). Erk1/2 polypeptide levels were modestly increased
after Mst1/2 inactivation; however, fractional Erk1/2 activation
was not altered, and in the HCCs, Erk1/2 levels and activation
were similar to wild-type liver (Figure S5). Thus inactivation of
Mst1/2 gives selective activation of mTOR complex1 without
apparent alteration of mTOR complex2 or in the Ras-MAPK
pathway. Levels of activated b-catenin (i.e., unphosphorylated
at Ser37 and/or Thr41) were unchanged by Mst1/2 inactivation
but elevated in a subset of HCC. Finally, p53 expression levels
were unchanged (Figure 2I), whereas MDM2 overexpression
was noted in 2/10 tumors (data not shown).
Mst1/2-Independent Regulation of Yap1 in MEFs
Previous in vitro studies have shown that cellular contact
induces Ser127 phosphorylation and cytoplasmic retention of
Yap1 and that this regulatory pathway is important for contact
inhibition of proliferation (Zhao et al., 2007). The prevailing view
has been that the core Hippo pathway components are required
to regulate Yap1 phosphorylation and activity in mammalian
cells (Dong et al., 2007; Zhao et al., 2008a). However, the specific
requirement of individual pathway components in normal tissues
has not been tested (apart from T cells; Zhou et al., 2008). More-
over, whether the pathway of Yap1 regulation is universal or has
context-dependent circuitry has not been established. First, we
sought to investigate the role of Mst1/2 in Yap1 regulation using
immortalized mouse embryonic fibroblasts (MEFs). Consistent
with published resultswe found that increasing celldensity induced
Yap1(Ser127) phosphorylation in wild-type MEFs (Figure 3A).
Unexpectedly, basal and cell contact-induced Yap1(Ser127)phos-
phorylation was unimpaired in Mst1/Mst2/ MEFs (generated
by infection of MEFs from Mst1/Mst2F/ mice with a retro-
virus-expressing Cre recombinase) although these cells lost
Mob1(Thr12) phosphorylation (Figures 3A and 3C). Notably, in
wild-type MEFs, Mst1 and Mst2 are present exclusively as full-
length polypeptides lacking detectable active site phosphorylation
and confluence is not accompanied by detectable change in the
phosphorylation of Mst1/2 or of Mob1(Thr12) (Figure 3B). As with
Yap1(Ser127) phosphorylation, Lats1/2 activation loop (AL) phos-
phorylation was induced at high cell density regardless of Mst1/2Cstatus (Figure 3C). Identical results were observed in primary
(nonimmortalized) MEFs except that confluence induced clearcut
Lats1/2 carboxy-terminal phosphorylation in the primary MEFs
(Figure S6). In parallel with the contact-induced phosphorylation
of Yap1(Ser127), both wild-type and Mst1/Mst2/ MEFs
showed cytoplasmic translocation of Yap1 when grown to high
cell density (Figure 3D). Correspondingly, the Mst1/Mst2/
MEFs exhibited normal contact inhibition of proliferation (data not
shown). The present unexpected results demonstrate that in
MEFs, Mst1/2 are not the upstream regulators of Lats1/2 and
Yap1 in response to cell-cell contact.
Mst1/2 Inactivation in the Liver Results in Deregulation
of Mob1 and Yap1 but Not Lats1/2
Our results in MEFs indicate that either Mst1/2 do not have
a conserved function in regulating Lats/Yap1 or that the pathway
upstream of Yap1(Ser127) phosphorylation is operative in a
tissue- or context-specific manner. The Adeno-Cre system
provided an opportunity to study the early signaling events
accompanying acute ablation of Mst1/2 in the liver. We found
that the Mst1/2 null livers had sharp decreases in pMob1(Thr12)
and pYap1(Ser127) at the 3 and 8 day time points as well as in the
ensuing HCCs (Figure 4A). Levels of total Yap1 polypeptide were
increased following Mst1/2 inactivation (Figure 4A), whereas
Yap1 mRNA levels were unchanged (data not shown), suggest-
ing that the unphosphorylated form of Yap1 may be stabilized.
Unexpectedly, phosphorylation of Lats1/2 at the carboxy-
terminal and activation loop was minimally altered in the Mst1/2
null livers and was at comparable levels in HCC and normal liver.
Ndr1 and Ndr2 are the most closely related kinases to Lats1/2
and can also be activated by Mst1/2-mediated carboxy-terminal
phosphorylation (Vichalkovski et al., 2008). Mst1/2 inactivation
resulted in a modest decrease in Ndr1/2 carboxy-terminal and
activation loop phosphorylation (Figure 4A). These patterns
were also observed in livers and HCC from Albumin-Cre;
Mst1/Mst2F/F mice indicating that such changes were not a
secondary consequence of the Adeno-Cre infection (Figure 4B).
Consistent with the role of Yap1(Ser127) phosphorylation in
cytoplasmic retention of Yap1, cell fractionation experiments re-
vealed that Yap1 is almost entirely cytoplasmic in wild-type liver
but present at high abundance in the nuclei of Mst1/2 null liver
(Figure 4C, top panel) and almost entirely nuclear in HCC (Fig-
ure 4C, bottom panel). Immunohistochemical analysis confirmed
the overexpression and nuclear translocation of Yap1 in HCC
(Figure 4D). Moreover, the expression of the candidate Yap1
target genes, CTGF and AFP (Dong et al., 2007; Zhao et al.,
2008b), was significantly elevated in the Mst1/2 null liver and in
HCC (Figure 4E). Together, these data demonstrate that Mst1
and Mst2 are critical negative regulators of Yap1 activity in hepa-
tocytes in vivo and moreover suggest that a kinase other than
Lats1/2 may be responsible for Yap1 phosphorylation down-
stream of Mst1/2. Inasmuch as Yap1 overexpression has been
shown to promote liver overgrowth and HCC, it is likely that
the deregulation of Yap1 activity contributes to these pheno-
types in the Mst1/2 mutant mice.
To gain further insight into the identity of the hepatic Yap1
kinase, we fractionated mouse liver extracts by anion exchange
chromatography. The Yap1(Ser127) kinase activity of each
column fraction was assayed against prokaryotic recombinantancer Cell 16, 425–438, November 3, 2009 ª2009 Elsevier Inc. 429
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body to detect kinase activity (Figure 4F). In addition to the
elution of endogenous hepatic Yap1(Ser127-P), two peaks of
Yap1(Ser127) kinase activity were observed in chromatograms
from wild-type mouse liver (Figure 4F, arrow; fractions 13–15
and 20–23). Note that the later-eluting of these peaks of Yap1
kinase activity comigrates with Lats1, whereas neither peak
coelutes with Lats2. We next compared the chromatograms of
wild-type and Mst1/Mst2F/ liver extracts prepared 8 days
after injection of Adeno-Cre (Figure 4G). We found that the earlier-
eluting peak of Yap1(Ser127) kinase was entirely absent from the
Mst1/2 null liver, whereas the later-eluting peak of Yap1(Ser127)
kinase, which co-elutes with Lats1 (Figure 4F), was unaltered.
Hence, the liver contains an Mst1/2-dependent Yap1(Ser127)
kinase that is entirely distinct from Lats1 and Lats2. Furthermore,
consistent with the insignificant changes in Lats1/2 phosphoryla-
tion (Figures 4A and 4B), Lats1-catalyzed Yap1(Ser127) kinase
activity is largely unaffected by Mst1/2 inactivation (Figure 4G).
Mst1/2 Deficiency in the Liver Leads to Resistance
to Fas-Induced Apoptosis
Deregulation of the Hippo pathway in Drosophila and Yap1 over-
expression in mice results in both hyperproliferative and antia-
poptotic phenotypes (Zhao et al., 2008a). To test whether
Mst1/2 deficiency affected hepatocyte apoptosis in addition to
proliferation, we injected mutant mice and controls with anti-
Fas antibody, Jo-2, 8 days after Adeno-Cre administration.
Under these conditions, wild-type livers showed extensive hepa-
tocyte apoptosis, whereas Mst1/2 null livers were strongly pro-
tected from cell death as determined by histological examination
as well as by TUNEL staining and western blotting for cleaved
caspase-3 (Figures 5A–5C).
Yap1 Is Required for Proliferation of Mst1/2 Mutant
HCC Cell Lines
On the basis of the activation of Yap1 in mice with Mst1/2 inac-
tivation in the liver and the similar liver phenotypes of these mice
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Figure 3. Analysis of the Hippo Pathway in Mst1/Mst2/ MEFs
(A) Western blot of immortalized MEFs grown to low (L) and high (H) density. Note that high density induces pYap1 regardless ofMst1/2 status. In contrast, pMob1
strictly requires Mst1/2. The MEFs were generated from wild type orMst1/Mst2F/mice and infected with a retrovirus expressing Cre recombinase. The cells
were then immortalized by infection with a retrovirus expressing SV40 T Antigen.
(B) Western blot showing expression of full length (FL), amino terminal truncated (NT), and activated phosphorylated forms of Mst1 and Mst2 in liver and MEFs.
(C) Western blot showing that the induction of Lats1/2 activation loop (AL) phosphorylation in MEFs at high cell density does not require Mst1 or Mst2.
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MEFs; scale bars represent 30 mm.430 Cancer Cell 16, 425–438, November 3, 2009 ª2009 Elsevier Inc.
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sought to assess whether Yap1 is critical for the tumorigenicity
of Mst1/2 mutant HCC. To this end, we first tested whether
Yap1 is under Mst1 regulation in an HCC cell line derived from
the mouse model (designated HCC-1). We introduced lentivi-
ruses expressing either GFP alone or in combination with Mst1
into HCC-1 cells; infection rates were reproducible 40%–60%
as reflected by microscopy for GFP. Western blot analysis—of
both unsorted cells or following GFP FACS—showed that
Mst1 restored detectable Mob1 phosphorylation and induced
pronounced phosphorylation of Yap1(Ser127) (Figure 6A). The
fact that Lats1/2 phosphorylation was unaffected (Figures 6A
and 6B) was in line with our earlier observation that acute inacti-
vation of hepatic Mst1/2 has little impact on Lats1/2 carboxy-
terminal phosphorylation in vivo (Figure 4A). Hence, Mst1/2
appear to regulate Yap1 in a Lats1/2-independent manner in
hepatocytes and in these HCC cells. Notably, Lats1/2 is prob-
ably capable of phosphorylating Yap1(Ser127) in HCC1 cells in-
asmuch as H2O2—which strongly activated Lats1/2 in the Mst1/
2 null HCC cells—induced a modest increase in Yap1(Ser127)
phosphorylation (Figure 6B), presumably attributable in part to
Lats1/2. The presence of Mst1, which was also activated by
H2O2 (as demonstrated by the increased Mob1 phosphoryla-
tion), did not alter the extent of basal Lats1/2 activation, but
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Figure 4. Mst1/2 Regulate Yap1 Phosphorylation and Cytoplasmic Retention in the Liver
(A) Western blot of liver lysates prior to (day 0) or at 3 and 8 days after Adeno Cre injection of mice with the indicated parental genotypes; an HCC is shown at the
far right. Note that elimination of Mst1/2 leads to immediate loss of pYap1 and pMob1. The Mst1/2 site at the carboxy terminus (CT) of pLats1/2 is minimally
affected, whereas there is a delayed and transient decrease of Lats1/2 activation loop (AL) phosphorylation. However, both Lats1/2 sites in the HCC are phos
phorylated at wild type levels. Mst1 and Mst2 are shown in Figure 2A.
(B) Western blot analysis of wild type liver as well as normal liver (N) and HCC (T1 and T2) from an Albumin Cre;Mst1/Mst2F/F mouse.
(C) Western blots of cytoplasmic (C) and nuclear (N) fractions from wild type and Mst1/Mst2F/ livers 8 days after Adeno Cre injection (left) and from a murine
HCC (right).
(D) IHC analysis of Yap1 expression in wild type liver and in HCC; scale bars represent 250 mm.
(E) qPCR analysis of CTGF and AFP mRNA expression in wild type and Mst1/Mst2F/ livers 8 days after Adeno Cre delivery and in murine HCC (data is mean
for three specimens per group; standard error of the mean is shown).
(F) Hepatic Yap1(Ser127) kinases. An extract of normal mouse liver was separated by anion exchange chromatography and each fraction was assayed for the
ability to catalyze the phosphorylation of a prokaryotic recombinant GST Yap1 at Ser127 (arrow) as detected by immunoblot (top panel). The asterisk marks
endogenous hepatic Yap1. The middle and lowest panels show the elution of the endogenous Lats1 and Lats2. Note that two peaks of Yap1(Ser127) kinase
activity are present, eluting in fractions 13 15 and 20 23. Lats1 coelutes with the latter peak of Yap1(Ser127) kinase, whereas Lat2 elutes in the interval between
the Yap1 kinase peaks.
(G) Yap1(Ser127) kinase activity in fractions from livers from Adeno Cre treated wild type and Mst1/Mst2F/ mice. Recombinant Yap1 (arrows) and endog
enous Yap1 (*) are indicated. Note that the earlier eluting peak of Yap1(Ser127) kinase activity (fractions 13 15) is absent in theMst1/2 deficient liver, whereas the
later eluting activity (fractions 20 22) is unaffected by Mst1/2 loss.Cancer Cell 16, 425–438, November 3, 2009 ª2009 Elsevier Inc. 431
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expected, the increased Yap1 phosphorylation in the Mst1-
expressing HCC-1 cells resulted in decreased Yap1 nuclear
residence as reflected by cell fractionation studies (Figure 6C).
BrdU-DAPI labeling studies showed that Mst1 increased the
proportion of HCC-1 cells in the G1 cell-cycle phase from 23%
to 43% (Figure 6D). Mst1 restoration also led to a pronounced
increase in the proportion of early apoptotic cells (13.97% versus
2.37%) and late apoptotic cells (5.78% versus 0.68%) (Figure 6E)
and induction of caspase-3 cleavage (Figure 6F). These cells
also showed decreases in expression of c-Myc expression and
cyclins D3 and E (Figure 6F) and a marked reduction in cell prolif-
eration, colony formation, and ability to grow in soft agar (Fig-
ure 6G and data not shown). Hence, Mst1 expression inactivates
Yap1 and reverts the tumorigenic growth of HCC-1 cells.
To directly test whether Yap1 is required for tumor mainte-
nance ofMst1/2 null HCC, we introduced lentiviruses expressing
Yap1 shRNAs into HCC-1 cells. We find that Yap1 knockdown
induced caspase 3 cleavage and a complete loss of c-Myc poly-
peptide as well as decreased expression of cyclin D3 and cyclin
E (Figure 7A). Yap1 shRNA expressing cells show a pronounced
alteration in cell cycle distribution (Figure 7B); cells in G1
increase from 28.6% to 44.8%, whereas cells in S phase
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Figure 5. Mst1/2 Deletion Protects against Fas Induced Apoptosis
(A) Wild type and Mst1/Mst2F/ mice were injected with Adeno Cre and 8
days later were treated with either vehicle or anti Fas antibody (Jo 2). Livers
were harvested 3 hr after treatment and analyzed by TUNEL staining. The
Mst1/2 deficient livers (Mst1/2/) were resistant to Fas induced apoptosis.
Scale bars represent 125 mm.
(B) Quantitation of TUNEL staining; n = 3 (error bars show standard deviation).
(C) Western blot analysis of liver lysates shows the upregulation of cleaved
caspase 3 (CL) in anti Fas treated mice but not Mst1/2 deficient mice.432 Cancer Cell 16, 425–438, November 3, 2009 ª2009 Elsevier Incdecrease from 56.8% to 36.55%. Yap1 depletion resulted in a
high level of apoptosis (Figure 7C; 28.47% versus 1.62% early
apoptosis; 4.44% versus 1.02% late apoptosis). The Yap1-defi-
cient cells are unable to form colonies at low density, to sustain
proliferation, or to grow in soft agar (Figures 7D–7F). These data
indicate that Yap1 is necessary to both sustain proliferation and
suppress apoptosis inMst1/2 null HCC. Thus Mst1/2-dependent
phosphorylation and inactivation of Yap1 is critical for tumor
suppression in the liver.
pYAP1, pMOB1, and the Cleaved, Active MST1 Catalytic
Fragment Are Frequently Lost in Human HCCs
Previous studies have reported that MST1/2 activity and expres-
sion of the candidate MST1/2 regulators RASSF1A and NORE1B
are reduced in most human HCCs compared to normal liver
(Calvisi et al., 2006; Macheiner et al., 2009). Moreover, whereas
YAP1 is exclusively cytoplasmic in the normal liver, it has
been reported that 50% of human HCC specimens exhibit
nuclear staining for YAP1 (Dong et al., 2007; Zhao et al., 2007).
Based on these data and our observation that loss of
Yap1(Ser127) phosphorylation due to Mst1/2 inactivation results
in nuclear translocation of Yap1 in the mouse liver, we sought to
address whether pYAP1(Ser127) is lost in human HCC and
therefore may contribute to its pathogenesis. To this end, we
analyzed expression of MST1/2-YAP1 signaling components in
a series of matched HCC and normal liver specimens by immu-
noblotting (Figure 8). As in the mouse liver, all normal human
liver specimens exhibited robust expression of total YAP1 and
pYAP1(Ser127). The MOB1 polypeptide immunoblot visualizes
two closely spaced bands with the upper predominant (Figure 8);
on p-MOB1 immunoblot, the lower band is usually the predom-
inant signal. MST1 and MST2 are readily visualized by immuno-
blot and in 19/21 normal livers and a substantial fraction of MST1
is present as a cleaved 34 kDa polypeptide (Figure 8), corre-
sponding to the pattern seen in normal mouse liver. These
patterns are significantly altered in the majority of HCCs. First,
YAP1(Ser127) phosphorylation is markedly reduced or absent
in 7/21 HCCs (2, 3, 5, 10, 11, 13, and 15); moreover, in four
HCCs (4, 6, 12, and 15) the level of total YAP1 polypeptide is
substantially elevated. Thus, in nearly half of these unselected
HCCs, YAP1 is underphosphorylated and/or overexpressed,
both circumstances likely to promote YAP1 nuclear localization
as previously reported. In all but six of the HCCs (1, 6, 7, 13,
14, and 21), the level of p-MOB1 is markedly reduced as
compared to the normal liver. Inasmuch as MOB1 is a highly
specific MST1/2 substrate, this argues for a marked reduction
in MST1/2 kinase activity (and/or increase in MOB1-phospha-
tase activity) in these HCCs. Expression of the MST1 and
MST2 56–60 kDa polypeptides is well preserved in the HCCs
(except in 7 and 21); however, in 13/21 HCCs, the 34 kDa
MST1 polypeptide is absent despite its ready visualization in
the paired normal liver. We have not assayed directly MST1/2
kinase in these samples, and immunoblotting of these lysates
with anti-MST1/2(p-Ser183/180) exhibits numerous nonspecific
bands near 55–60 kDa and 34 kDa, precluding this estimate of
MST1/2 kinase activity. Nevertheless, the lack of the 34 kDa
constitutively active catalytic fragment, which is the predominant
active form of MST1/2 in normal mouse liver, may contribute to
a lowered MST1/2 activity in these HCCs. It is notable that all.
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Mst1/Mst2 Regulate Liver Size and Tumorigenesisbut one (13) of the seven HCCs with diminished pYAP1 exhibit
diminished p-MOB1 and 5/7 lack expression of the MST1
34 kDa fragment (3, 5, 11, 13, and 15). Hence, loss of negative
regulation of YAP1, most often due to diminished MST1/2
activity, is a common occurrence and likely pathogenetic factor
in human HCC.
DISCUSSION
We have demonstrated that Mst1 and Mst2 act in a redundant
manner to maintain quiescence in the adult liver and that their
dual inactivation leads to immediate Yap1 activation, liver over-
growth, resistance to Fas-induced apoptosis, and rapid HCC
development. We provide evidence that Yap1 nuclear residence
and activation, resulting from loss of Ser127 phosphorylation,
is critical for HCC development and maintenance in the setting
of Mst1/2 deficiency. In addition, defects in MST1/2-YAP1
signaling are present in a subset of human HCCs.
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Figure 6. Mst1 Restoration Inactivates
Yap1 and Reverts Tumorigenicity of Mst1/
2 Deficient HCC Cells
(A) The HCC 1 cell line, derived from an HCC
arising in an Mst1/Mst2F/ mouse, was in
fected with lentiviruses that express GFP alone
or in combination with Mst1. HCC 1 cells were
either FACS sorted for GFP (+) or were unsorted
(). The western blot of cells harvested 96 hr after
lentiviral infection shows that Mst1 induces Yap1
and Mob1 phosphorylation, whereas Lats1/2 car
boxy terminal (CT) and activation loop (AL) phos
phorylation are unaffected.
(B) Western blot of sorted HCC 1 cells that were
either untreated () or exposed to 0.5 mM H2O2
(+). H2O2 induces strong Lats1/2 phosphorylation
independent of Mst1/2, whereas Yap1 phosphor
ylation is increased more by Mst1 than by H2O2
in the absence of Mst1/2.
(C) Western blots of cytoplasmic (C) and nuclear
(N) fractions of unsorted HCC 1 cells showing
that Mst1 promotes increased phosphorylation
and cytoplasmic retention of Yap1.
(D) BrdU/DAPI staining and flow cytometry of HCC
cells 72 hr after infection. Mst1 induces an
increase in G1 content (bottom left quadrant) and
a decrease in S phase (top quadrant) cells.
(E) Annexin V/7 AAD staining and flow cytometry
of HCC 1 cells 48 hr post infection. Mst1 induces
early apoptosis (bottom right quadrant) and late
apoptosis (top right quadrant).
(F) Western blot expression of unsorted HCC 1
cells analyzed 96 hr post infection showing that
Mst1 induces cleavage of caspase 3 (CL) and a
reduction in expression of c Myc, cyclin D3, and
cyclin E.
(G) Mst1 reexpression suppresses HCC 1 colony
formation (left) and growth in soft agarose (right).
Error bars show standard deviation.
The ability of Mst1/2 to regulate
Yap1(Ser127) phosphorylation is antici-
pated by the ‘‘Hippo’’ paradigm. The
present data indicate, however, that in
the liver Mst1/2 controls Yap1 phosphorylation through a kinase
other than Lats1/2. This and other recent work in Mst1/2-defi-
cient mice illustrate two noteworthy features of Mst1/2 signaling.
First, in all cellular contexts examined thus far, loss ofMst1 (Zhou
et al., 2008), orMst1 plusMst2, results in the loss of Mob1(Thr12/
Thr35) phosphorylation. Thus Mob1 phosphorylation, which has
been shown to mediate, in part, Mst1/2 inhibition of cell cycle
progression (Praskova et al., 2008), is a reliable and apparently
specific indicator of Mst1/2 activity in vivo. Second, it is apparent
that Mst1/2 signaling and Yap1 phosphorylation exhibit an unex-
pected diversity in addition to the relationships predicted by
the Drosophila Hippo-Lats-Yorkie tumor-suppressor pathway.
Thus, in mouse liver, Mst1/2 signal through an unknown interme-
diary kinase to control Yap1(Ser127) phosphorylation. In the
mouse T cell, Mst1 activated by anti-CD3 signals through
Mob1 and unknown effectors (other than Yap1) to activate integ-
rin clustering/activation and to inhibit naive T cell proliferation
(Zhou et al., 2008). MEFs present yet another arrangement;Cancer Cell 16, 425–438, November 3, 2009 ª2009 Elsevier Inc. 433
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Mst1/Mst2 Regulate Liver Size and TumorigenesisMEFs achieving confluence exhibit activation of Lats1/2, Yap1
phosphorylation, and egress of Yap1 from the nucleus; however,
these events are unaltered despite the deletion of Mst1 and
Mst2 and the loss of Mob1 phosphorylation. Therefore, it is clear
that Mst1/2-Lats1/2-Yap1 signaling varies according to cell
type and cell context; there exist Lats1/2 activators other than
Mst1/2 and Yap1(Ser127) kinases other than Lats1/2. It is also
apparent that important Mst1/2 substrates apart from Mob1,
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Figure 7. Yap1 Is Required for Tumorigenicity of Mst1/2 Null HCC Cells
(A) Western blots of lysates from HCC 1 cells infected with lentiviruses expressing scrambled or Yap1 shRNAs and analyzed at day 6 post infection. Yap1 shRNA
silences Yap1 expression and results in caspase 3 cleavage (CL) and reduction in full length (FL) caspase 3.
(B) BrdU/DAPI staining and flow cytometry. Yap1 shRNA increases the proportion of HCC 1 cells in G1 (bottom left quadrant) and decreases cells in S phase
(top quadrant).
(C) Annexin V/7 AAD staining and flow cytometry. Yap1 shRNA induces early apoptosis (bottom right quadrant) and late apoptosis (top right quadrant).
(D) HCC 1 cells expressing Yap1 shRNA are unable to form colonies in clonogenic assays.
(E and F) Yap1 knockdown prevents the proliferation of HCC 1 cells as determined by MTT assay (E) and suppresses growth in soft agarose (F).434 Cancer Cell 16, 425–438, November 3, 2009 ª2009 Elsevier Inc.
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Mst1/Mst2 Regulate Liver Size and TumorigenesisLats1/2, and Ndr1/2 (Vichalkovski et al., 2008) remain to be
discovered.
Previous reports have shown that Yap1 overexpression in
mice promotes the development of HCC (Dong et al., 2007; Zen-
der et al., 2006) and that increased nuclear abundance of YAP1 is
present in about 50% of human HCCs (Dong et al., 2007; Zhao
et al., 2007). The mechanisms of YAP1 deregulation in human
HCCs were not defined in these studies. Although amplification
of the YAP1 locus may lead to YAP1 overexpression in some
HCCs, such amplification appears to be relatively uncommon,
restricted to 5%–10% of tumors (Zender et al., 2006). On the
other hand, the present work points toward loss of YAP1(Ser127)
phosphorylation as being an important mechanism for YAP1
deregulation in human HCC, as we have observed this alteration
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Figure 8. Immunoblot Analysis of YAP1, MOB1, and MST1/2 in
Human HCC
Western blot analysis of 21 paired samples of nontumorous liver (N) and HCC
(T) from the same patient. Patients 2, 3, 5, 10, 11, 13, and 15 exhibit substan
tially lower pYAP1 in the tumor relative to the nontumorous liver. Patients 4, 6,
12, and 15 exhibit pYAP1 polypeptide overexpression in the tumor. The
majority of HCCs exhibit much lower pMOB1 relative to the paired nontumo
rous liver. The MST1 34 kDa polypeptide fragment is lacking in the tumors
while present in the nontumorous livers of patients 3, 4, 5, 7, 8, 9, 11, 13, 15,
17, 19, 20, and 21, whereas only patients 6 and 18 exhibit detectable
34 kDa MST1 in their tumors but little or none in their nontumorous livers.
The associated clinical information is presented in Table S1.Cin30% of HCC specimens (Figure 8). Significantly, we observed
a close correlation between loss of pYAP1(Ser127) and loss of
pMOB1(Thr12) in the human HCC specimens, indicating that
low MST1/2 activity is likely responsible for most instances of
low YAP1(Ser127) phosphorylation. Further studies will be
required to demonstrate directly the functional contributions of
MST-YAP1 signaling defects to human HCC pathogenesis.
Although our work suggests that Yap1 is a major mediator of
phenotypes downstream of Mst1/2 in the liver, we cannot rule
out the possibility that there are other critical effectors of the
pathway that contribute to these phenotypes. In this regard, it
is notable that the transcriptional coactivator Taz, a potential
oncogene (Chan et al., 2008; Lei et al., 2008), shares 45%
homology to Yap1 throughout its sequence, and in vitro studies
suggest that these proteins can be regulated through compa-
rable mechanisms (i.e., by Lats-mediated phosphorylation of a
conserved motif resulting in cytoplasmic sequestration) (Lei
et al., 2008). We find that Taz phosphorylation at this site is
reduced following Mst1/2 inactivation in the liver (Figure S4A),
suggesting that Taz is negatively regulated by Mst1/2. However,
levels of Taz polypeptide are also decreased in the Mst1/2 liver
and in HCC, indicating that Taz is unlikely to play a positive
role in overproliferation or tumorigenesis in this setting.
Our data show that Mst1/2 are constitutively active in the
quiescent liver and that they mediate sustained phosphorylation
of Mob1 and Yap1. A key outstanding question is the nature of
the upstream activating signals in this pathway. The importance
of this question is emphasized by the finding that despite the
frequent loss of pMOB and pYAP1 in human HCCs, the expres-
sion of the full-length MST1 and MST2 polypeptides is main-
tained in nearly all these tumors. Consequently, it is likely that
diminished upstream inputs are the basis for deficient MST1/2
activity in these tumors. Three apparently independent mecha-
nisms for upstream regulation of the Mst1/2 kinases have been
identified thus far. In the Drosophila Hippo pathway, the activity
of the Mst1/2 ortholog, Hippo, is controlled, at least in part,
by cell-cell contact, mediated by the atypical cadherin, Fat,
and the membrane-associated FERM-domain polypeptides,
Expanded and Merlin (Reddy and Irvine, 2008). In mammals,
NF2/MERLIN has been reported to regulate YAP1 cytoplasmic
retention in neural tumor-derived cell lines (Zhao et al., 2007).
Similarly, overexpression of FRMD6, the closest mammalian
homolog of Expanded, can repress the activity of a Yap1
transcriptional reporter (Zhao et al., 2007). However, the physio-
logical significance of this pathway and its role in the regulation
of Mst1/2 in liver has not been defined. A second mechanism
for Mst1/2 activation involves ligand-mediated receptor signal-
ing and the Rassf1/Nore proteins that are found in a constitutive
complex with Mst1/2 in cell lines that express these polypep-
tides (Avruch et al., 2009). In T cells, Mst1 is activated by stimu-
lation of antigen or chemokine receptors, which induce associa-
tion of the Nore1B/Mst1 complex with activated Ras-like
GTPases, specifically Rap1 and Rap2. The Nore1B/Mst1
complex is required in T cells for Rap1-GTP-induced integrin
clustering and in naive T cells for restraint of proliferation. Hippo
pathway components (e.g., a cadherin, ERM proteins, or WW45)
are not involved in the GTPase regulation of the Nore1/Mst1
complex. Inasmuch as RASSF1A, NORE1A, and NORE1B
have been shown to be epigenetically inactivated in wide rangeancer Cell 16, 425–438, November 3, 2009 ª2009 Elsevier Inc. 435
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et al., 2007; Macheiner et al., 2009) it is plausible that their dimin-
ished expression might result in defective regulation of MST1/2
signaling.
A third mechanism of Mst1/2 regulation, probably operational
in the liver, appears to be at the level of caspase-dependent
cleavage. Previous studies have shown that Mst1 and Mst2 exist
as 56 kDa full-length polypeptides or as truncated 34–36 kDa
amino-terminal forms that arise due to caspase-dependent
cleavage during apoptosis (Graves et al., 1998; Lee et al.,
2001). We find that the majority of Mst1 in normal mouse liver
exists as a 34–40 kDa polypeptide, and a significant fraction of
Mst2 is also found in a truncated form. Moreover, the vast
majority of the activated Mst1/2 kinase in liver (i.e., forms phos-
phorylated at the activation loop) are the short Mst1/2 polypep-
tides, whereas spleen and MEFs exhibit only the presence of the
full-length forms. Hence the cleavage of Mst1/2 appears to be
a regulated, tissue-specific process. The truncated forms have
lost their autoinhibitory and SARAH domains, are thus highly
active, and are released from upstream regulation by the
WW45 or Rassf family polypeptides. The truncated Mst1/2 poly-
peptides are preferentially localized to the nucleus and have an
altered substrate specificity (Anand et al., 2008; Ura et al.,
2001); however, their potency in regulation of Yap1 as compared
to the full-length Mst1/2 polypeptides remains to be defined. The
proportion of Mst1 exhibiting cleavage in the liver is much higher
than that of Mst2. In addition, Mst1/ livers exhibit a significant
reduction in pYap1 and pMob1 compared to wild-type livers,
whereas there is only a modest decrease in pYap1 in pMob1 in
Mst2/ livers (Figure S7). Hence, although both Mst1 and
Mst2 are required for complete loss of Yap1 phosphorylation in
the liver, Mst1 plays the more important role. Caspase-3-depen-
dent cleavage of Mst1 is required for myoblast differentiation
in vitro, in the absence of any detectable apoptosis (Fernando
et al., 2002; Murray et al., 2008). This observation is in keeping
with emerging data from embryonic stem cells and hematopoi-
etic stem cells showing that caspase-3 activation may generally
contribute to cellular differentiation through proteolysis of
multiple targets (Yi and Yuan, 2009). Thus, we surmise that the
truncated, constitutively activated form of Mst1/2 may play an
important role in maintenance of hepatocytes in a differentiated,
nonproliferative state.
Our data also demonstrate the importance of endogenous
Mst1/2 in apoptotic regulation in an intact mammalian organism,
consistent with the loss of developmental apoptosis seen with
Drosophila Hippo loss of function (Figure 5). As to the mecha-
nism Mst1/2-dependent apoptosis, the Jo-2 anti-Fas antibody
does cause a small increase in Mob1 phosphorylation indicative
of Mst1/2 activation, but surprisingly is accompanied by a reduc-
tion in Yap1 phosphorylation (Figure S8). Thus, whether and to
what extent the modest activation of Mst1/2 by the Fas agonist
contributes to the rapid activation of apoptosis by Fas is unclear.
The protective effect of Mst1/2 ablation against Fas-induced
apoptosis seems more likely to reflect enhanced expression of
Yap1-dependent transcriptional outputs that confer resistance
to apoptosis (Zhao et al., 2008b).
HCC is the fifth most common malignant neoplasm worldwide
and third most frequent cause of cancer-related death (Llovet
et al., 2003). Only a minority of patients are eligible for potentially436 Cancer Cell 16, 425–438, November 3, 2009 ª2009 Elsevier Inccurative surgery and conventional chemotherapeutic approaches
are ineffective in thisdisease (Villanueva et al., 2008). While molec-
ularly targeted agents have increased survival in patients with
advanced HCC, only a subset of patients show responses and
theseagents donot achieve cures. It is clear that a betterdefinition
of the molecular pathogenesis of HCC and the molecular classifi-
cation of subsets of tumors are important steps in the design of
improved therapeutic strategies. Our work shows that loss of
YAP1 phosphorylation specifies of a subset of human HCC. In
addition, we have observed that, as in the murine HCCs, YAP1
knockdown in some human HCC cell lines blocks colony forma-
tion in vitro and promotes apoptosis (data not shown). Hence,
elucidating the critical YAP1 target genes may point to effective
therapeutic targets for a subset of HCC. In future studies, it will
also be important to define whether loss of YAP1 phosphorylation
is associated with other well-defined molecular alterations in HCC
and to determine what is the prognostic significance of this sub-
group of tumors.
EXPERIMENTAL PROCEDURES
Animals
The generation of the Mst2F and Mst2 alleles and the analysis of the Mst1/
Mst2/ embryos are described in detail in the Supplemental Experimental
Procedures. All mice used in this study were maintained on a mixed genetic
background (C57BL/6; 129/Sv). Mouse work was done with Institutional
Animal Care and Use Committee approval and in strict accord with good
animal practice as defined by the Office of Laboratory Animal Welfare.
Materials and Reagents
Antibodies against Mst1, Mst2, pMst1 (Thr183P)/pMst2 (Thr180P), Lats1,
pLats carboxy terminal, pLats AL, Mob1, and pMob1(Thr12) were described
previously (Praskova et al., 2008). All other antibodies and assay reagents
were obtained from commercial sources as described in Supplemental Exper
imental Procedures. Ad5CMVCre (Ad Cre) virus was purchased from the Gene
Transfer Vector Core at the University of Iowa.
Cell Culture and Molecular Methods
Methods for cell culture, adeno and lentiviral mediated gene transfer, subcel
lular fractionation, immunoblotting, immuno , cyto , and histochemistry,
assays for cell proliferation, apoptosis, and mRNA abundance are described
in Supplemental Experimental Procedures.
Hepatic Yap1(Ser127) Kinase Activities
Fresh mouse livers were homogenized in 20 mM Tris HCl (pH 7.6), 0.3 M
sucrose, 1 mM EDTA, 5 mM EGTA, 1 mM DTT, 2.5 mM sodium pyrophos
phate, and 1 mM b glycerophosphate, containing a proteinase inhibitors tablet
(Roche). The supernatant of a 100,000 3 g, 2 hr centrifugation was applied to
a HiTrapHP Q column (GE Healthcare) equilibrated in 20 mM Tris HCl (pH 7.6),
1 mM EDTA, and 1 mM NaF. Elution was carried out with 4 column volumes of
an NaCl gradient from 0.1 M to 0.6 M. Forty fractions were collected and an
aliquot of each was assayed for Yap1(Ser127) kinase activity by incubation
with prokaryotic recombinant GST Yap, 10 mM Mg, and 100 mM ATP for
30 min at 30C. The kinase reactions were stopped by adding SDS sample
buffer and subjected to SDS PAGE and immunoblot as indicated.
Human Liver and HCC Samples
Human samples were obtained under informed consent from the Foundation
for Human Tissue and Cell Research (HTCR), Regensburg, Germany. Experi
ments were performed under HTCR and Massachusetts General Hospital
Institutional Review Board approval and are considered exempt. Biopsies
from specimens of normal liver tissue (distant from the tumor) and HCC
were collected snap frozen. Patients receiving hepatotoxic medication or
chemotherapy or patients with systemic disease known to affect the liver.
Cancer Cell
Mst1/Mst2 Regulate Liver Size and Tumorigenesiswere excluded. Diagnosis of HCC and normal liver was confirmed based on
histological findings by independent pathologists.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, one
table, and eight figures and can be found with this article online at http://
www.cell.com/cancer cell/supplemental/S1535 6108(09)00337 7.
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